劉 欣怡

Medicine & Life Sciences

1. Pseudomonas aeruginosa 100%
2. Levofloxacin 64%
3. Cross Infection 57%
4. Fluoroquinolones 50%
5. Teaching Hospitals 49%
6. Pneumonia 48%
7. Confidence Intervals 47%
8. Propensity Score 46%
9. Anesthesia 44%
10. Amikacin 37%
11. Cohort Studies 36%
12. General Anesthesia 32%
13. Mortality 31%
14. Ciprofloxacin 30%
15. ceftazidime drug combination avibactam 29%
16. Hepatocellular Carcinoma 28%
17. Dental Scaling 27%
18. Taiwan 26%
19. Amoebic Liver Abscess 26%
20. Antimicrobial Stewardship 26%
21. Pleural Empyema 25%
22. Escherichia coli 25%
23. Odds Ratio 24%
24. Fosfomycin 24%
25. Nitrofurantoin 24%
26. Randomized Controlled Trials 24%
27. Microbial Sensitivity Tests 23%
28. Carbapenems 23%
29. Coronavirus 22%
30. Empyema 22%
31. Sevoflurane 21%
32. Entropy 21%
33. Non-Randomized Controlled Trials 20%
34. Staphylococcal Infections 20%
35. Liver 19%
36. beta-Lactamases 19%
37. Klebsiella pneumoniae 19%
38. Intensive Care Units 18%
39. Methicillin-Resistant Staphylococcus aureus 18%
40. Pseudomonas Infections 18%
41. Migraine Disorders 18%
42. Anti-Bacterial Agents 18%
43. Microbial Drug Resistance 17%
44. Critical Care 17%
45. Coinfection 17%
46. Human Influenza 16%
47. Tazobactam Drug Combination Piperacillin 16%
48. Thoracic Surgery 16%
49. Chronic Kidney Failure 15%
50. Thorax 15%